Cancer in Denmark

IARC estimates 46,512 new cancer cases and 17,720 cancer deaths in Denmark in 2024; the commonest new cancers are prostate, breast and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 422 trials with a site there, 8 institutions, 18 companies and 11 people, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

46,512

all cancers

Deaths

17,720

all cancers

Incidence rate

345.1

per 100,000, age-standardised

Mortality rate

99.9

per 100,000, age-standardised

Cumulative risk

33.1%

of a cancer by age 74

Population

5,977,417

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	5,280	75.7	Prostate cancer
Breast	5,242	92.5	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	5,202	34.2	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	4,416	30.0	Colorectal cancer
Melanoma of skin	3,055	27.8	Melanoma
Bladder	2,466	15.8	Bladder & urothelial cancer
Non-Hodgkin lymphoma	1,613	12.2	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Pancreas	1,377	9.0	Pancreatic ductal adenocarcinoma
Leukaemia	1,106	9.3	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Kidney	1,078	9.1	Renal cell carcinoma

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	3,873	22.7	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	1,990	10.4	Colorectal cancer
Prostate	1,369	13.2	Prostate cancer
Pancreas	1,362	8.0	Pancreatic ductal adenocarcinoma
Breast	1,203	13.2	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Leukaemia	581	3.0	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Liver and intrahepatic bile ducts	568	3.5	Hepatocellular carcinoma
Bladder	561	2.6	Bladder & urothelial cancer
Brain, central nervous system	490	4.1	Glioma & glioblastoma
Stomach	487	3.1	Gastric & gastro-oesophageal junction cancer

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Denmark”, in Northern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

422 trials in OnCo · 127 recruiting overall

422 trials

Trial			Lead sponsor
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis NCT04910685	Phase 2/3	Recruiting	Blueprint Medicines Corporation	88	2026-10-07
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) NCT07209111	Phase 2	Recruiting	Merck Sharp & Dohme LLC	72	2026-10-07
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer NCT06072781	Phase 3	Recruiting	Verastem, Inc.	106	2026-10-07
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581	Phase 3	Recruiting	Eli Lilly and Company	416	2026-10-07
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract NCT07218380	Phase 3	Recruiting	Eli Lilly and Company	276	2026-10-07
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati NCT07195695	Phase 3	Recruiting	Boehringer Ingelheim	202	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer NCT06510374	Phase 3	Recruiting	Ferring Pharmaceuticals	112	2026-10-07
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) NCT07489495	Phase 3	Recruiting	Merck Sharp & Dohme LLC	99	2026-10-06
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip NCT06793215	Phase 3	Recruiting	Hoffmann-La Roche	288	2026-10-06
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) NCT07630974	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	29	2026-10-06
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	64	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354	Phase 3	Recruiting	Merck Sharp & Dohme LLC	281	2026-10-06
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult NCT07059845	Phase 2	Recruiting	AbbVie	85	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu NCT05533775	Phase 1/2	Recruiting	Hoffmann-La Roche	30	2026-10-06
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl NCT06824467	Phase 3	Recruiting	Merck Sharp & Dohme LLC	197	2026-10-06
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL NCT04924075	Phase 2	Recruiting	Merck Sharp & Dohme LLC	84	2026-10-06
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164	Phase 3	Recruiting	Merck Sharp & Dohme LLC	54	2026-10-06
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374	Phase 3	Recruiting	Merck Sharp & Dohme LLC	314	2026-10-06
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma NCT06697301	Phase 2/3	Recruiting	Eikon Therapeutics	127	2026-10-06
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624	Phase 3	Recruiting	Merck Sharp & Dohme LLC	288	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer NCT07166094	Phase 3	Recruiting	Genmab	177	2026-10-06
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	77	2026-10-06
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) NCT06395103	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	71	2026-10-06
waveLINE-003 NCT05139017	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	135	2026-10-06
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) NCT04728893	Phase 2	Recruiting	Merck Sharp & Dohme LLC	121	2026-10-05

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Denmark, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Denmark is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

Approvals

Denmark is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

From the country research ranking

Research funders: Danish Cancer Society; Novo Nordisk Foundation; Danish Cancer Society ≈ DKK 400 million/year (source).
Named in the ranking: Danish Comprehensive Cancer Center and National patient registries.

From the country ranking's hand-curated row; follow its source before relying on a figure.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Denmark's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Denmark, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Denmark's own sources.

A deep dive for Denmark is ranked 42 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today; Denmark fact sheet.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/dk.json; every country: /api/v1/countries.json.